Outlook Therapeutics (OTLK) Return on Sales (2015 - 2025)

Outlook Therapeutics (OTLK) reported Return on Sales of 1.45% for Q3 2025, up 1181.77% quarter-over-quarter from 0.13% in Q2 2025.

Outlook Therapeutics (OTLK) Return on Sales (2015 - 2025) Analysis & Trends

Outlook Therapeutics (OTLK) has 6 years of Return on Sales data on file, last reported at 1.45% in Q3 2025.

  • Return on Sales for Q3 2025 came in at 1.45%, changed N/A year-over-year; the trailing twelve-month figure through Sep 2025 was 0.13% (changed N/A YoY), and the FY2025 annual result was 0.44%, changed N/A from the prior year.
  • Return on Sales advanced to 1.45% in Q3 2025 per OTLK's latest filing, from 0.13% in the prior quarter.
  • Over five years, Return on Sales peaked at 1.45% in Q3 2025 and troughed at 0.13% in Q2 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROS (Qtr)
1 Alterity Therapeutics 788,338.31 Bn 788,338.28 Bn - -
2 Belite Bio 56,560.00 Bn 56,560.00 Bn - -
3 Quantum Biopharma 17,329.30 Bn 17,329.30 Bn - -
4 Legend Biotech 3,341.00 Bn 3,340.71 Bn 242.10 Mn 0.00%
5 Akari Therapeutics 1,727.91 Bn 1,727.91 Bn - -
6 Evaxion A 1,536.68 Bn 1,536.67 Bn - 0.00%
7 Psyence Biomedical 238.34 Bn 238.33 Bn - -
8 Vertex Pharmaceuticals 113.42 Bn 106.17 Bn 2.59 Bn 0.00%
9 Abivax 95.45 Bn 95.45 Bn - -
10 Outlook Therapeutics 51.13 Mn 43.39 Mn -21,888.00 -

Historic Data

Download Data
DateValue
Sep 30, 2025 1.45%
Jun 30, 2025 -0.13%
Sep 30, 2019 -0.02%
Jun 30, 2019 -0.08%
Mar 31, 2019 -0.16%
Dec 31, 2018 -0.09%
Sep 30, 2018 -0.16%
Jun 30, 2018 -0.11%
Mar 31, 2018 -0.10%
Dec 31, 2017 -0.02%
Sep 30, 2017 -0.02%
Jun 30, 2017 -0.18%
Mar 31, 2017 -0.27%
Dec 31, 2016 -0.63%
Sep 30, 2016 -0.21%
Jun 30, 2016 -0.45%
Mar 31, 2016 -0.04%
Dec 31, 2015 -0.17%
Sep 30, 2015 -0.36%
Jun 30, 2015 -0.09%